Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Movement Disorders

Movement Disorders

Subtypes of Movement Disorders

Parkinson's Disease 98 Tourette Syndrome 5 Essential Tremor 4 Multiple system atrophy 4 Tic disorders 1 Wilson Disease 1 Wilson's disease 1

110 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Movement Disorders

8 trials tracked for Movement Disorders.

8Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3 Other / NA 5
  1. Phase 2 Heart Rate Variability in Response to Metformin Challenge Completed
  2. Phase 2 Dyskinesia in Parkinson's Disease (Study P04501) Completed
  3. Phase 2 Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175) Completed
  4. N/A BIS and Entropy in Deep Brain Simulation Completed
  5. N/A Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System Completed
  6. N/A A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling Completed
Show 2 more trials
  1. N/A North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 Completed
  2. N/A Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1) Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Movement Disorders: current evidence & treatments

Parkinson's disease (PD) is a complex movement disorder with multiple genetic, environmental, and mechanistic factors. Genetic studies have identified strong risk factors: heterozygous GBA1 L444P carriers have ninefold higher odds of PD compared to non-carriers (OR 9.19, 95% CI 6.94–12.16) 9, and bipolar disorder is associated with a 3.65-fold higher risk of PD (HR 3.65, 95% CI 2.16–6.17) 3. Six novel loci and nine recessive loci have been identified for young-onset PD in European ancestry 4. Additionally, a mitochondrial polygenic score is linked to alpha-synuclein seeding in LRRK2-related PD 17. Mechanistically, the exercise-microbiota-queuine-tRNA axis may influence mitochondrial function and proteostasis 1, and RNA editing alterations are observed in PD patients, with distinct patterns between brain and peripheral blood 18. Ferroptosis-immune crosstalk is also implicated in CNS diseases including PD 24.

Diagnostic and therapeutic advances have been reported. Quantitative susceptibility mapping MRI reveals distinct iron deposition patterns differentiating PD from atypical parkinsonian syndromes: substantia nigra susceptibility is increased in PD (SMD 1.24), putaminal susceptibility is higher in MSA, and pallidal susceptibility is higher in PSP 7. MRI volumetric differences are seen in PD patients with mild cognitive impairment versus cognitively normal PD 25. For treatment, continuous subcutaneous foslevodopa/foscarbidopa improves off time in PD, with no significant between-group difference between prior DBS and no prior DBS groups 8. Deep brain stimulation (DBS) improves motor function and reduces levodopa needs regardless of GBA mutation status 16, and DBS modestly improves freezing of gait (FOG-Q MD -2.99) 22. Prasinezumab showed non-significant delay in motor progression versus placebo in early-stage PD 11. GLP-1 agonists showed limited motor benefit but a small improvement in quality of life (PDQ-39 MD -0.75) 21. Acupuncture moderately improves sleep quality in PD (MD 14.52) 23. Sensory cueing improves gait velocity (somatosensory MD 0.12 m/s, visual MD 0.11 m/s) and stride length (visual MD 11.46 cm) 15. Combined motor and cognitive therapy shows mixed benefits: sequential treatment improved balance but not functional mobility 12. VR and physiotherapy are equally effective for balance 14.

Non-motor symptoms in PD are complex; current classifications inadequately reflect their interrelationship 2. Tourette syndrome involves multilevel dysfunction linking internal states to motor output via negative reinforcement 10. Nocebo effects can be induced through negative verbal suggestion in chronic conditions including PD 20. Nutrient and metabolite interventions for neurodegenerative diseases show inconsistent clinical translation 6. AI applications for protein misfolding diseases, including PD, are being explored 19. The HMC3 microglial model illuminates neurodegenerative mechanisms in PD 5. TCM metabolites show neuroprotective potential in zebrafish models 13.

Latest findings

AI-generated synthesis of 25 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review organizes pharmacological strategies targeting gut-brain axis for neurological and psychiatric disorders
Neurology Sys. Review
Review organizes pharmacological strategies targeting gut-brain axis for neurological and psychiatric disorders Could targeting gut health help treat brain disorders?
A systematic review summarizes mechanisms of microbiota–gut–brain axis dysfunction and organizes existing pharmacological strategies for con…
Treating brain disorders like Parkinson's and depression may involve targeting the gut-brain connection to reduce shared inflammation.
Frontiers Apr 2, 2026
Fatal serotonin syndrome in Parkinson's patient on rasagiline after sequential SSRI administration
Psychiatry
Fatal serotonin syndrome in Parkinson's patient on rasagiline after sequential SSRI administration Case report describes fatal serotonin syndrome in older Parkinson's patient on multiple medications
A case report describes a 72-year-old Parkinson's patient on rasagiline who developed fatal serotonin syndrome after sequential sertraline a…
A 72-year-old Parkinson's patient died after taking two antidepressants with a genetic makeup that slowed drug processing, causing fatal ser…
Frontiers Apr 1, 2026